ATEZOLIZUMAB (Tecentriq) prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UPMC Health Plan requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for ATEZOLIZUMAB (Tecentriq): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UPMC Health Plan reviews ATEZOLIZUMAB (Tecentriq) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
ATEZOLIZUMAB (Tecentriq)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Triple-negative breast cancer indication (voluntarily withdrawn 2021 — plans cite this for all TNBC denials)
- SCLC maintenance denial
- Off-label NSCLC combinations
Brand: Tecentriq. PD-L1 inhibitor. SubQ formulation (Tecentriq Hybreza) FDA-approved September 2024. Note: TNBC accelerated approval withdrawn August 2021 — be careful citing this indication in appeals.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when an UPMC Health Plan denial sticks and the patient needs bridge access while appealing.
How UPMC Health Plan approaches Immune checkpoint inhibitors PAs
For ATEZOLIZUMAB (TECENTRIQ), check whether the current UPMC Health Plan Immune checkpoint inhibitors policy cites specialty drug pa. Pharmacy-benefit review for ATEZOLIZUMAB (TECENTRIQ) at UPMC Health Plan is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with UPMC Health Plan; if denied, use the filing date and route printed on that denial notice. Off-label oncology appeals at UPMC Health Plan carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. UPMC Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus an applicable, current clinical source supporting ATEZOLIZUMAB (Tecentriq)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an UPMC Health Plan denial on DenialHelp.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for ATEZOLIZUMAB (Tecentriq) prior auth?
UPMC Health Plan's typical PA packet for ATEZOLIZUMAB (Tecentriq): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UPMC Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for ATEZOLIZUMAB (Tecentriq) at UPMC Health Plan?
Preparation scenarios to check against the current notice and policy include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. These are not measured frequency claims. For ATEZOLIZUMAB (Tecentriq), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does UPMC Health Plan cover off-label use of ATEZOLIZUMAB (TECENTRIQ) supported by NCCN compendium?
UPMC Health Plan may consult the NCCN Drugs & Biologics Compendium for oncology coverage. For off-label ATEZOLIZUMAB (TECENTRIQ), cite the current compendium entry by version and table, name the evidence-block category, and attach the supporting clinical-trial or meta-analysis reference. Verify the member-specific coverage rule and timing before relying on this preparation guide. Pharmacy-benefit handling is routed through UPMC Pharmacy Network (in-house, integrated payer-provider). External-review escalation for UPMC Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with UPMC Health Plan on ATEZOLIZUMAB (Tecentriq)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the ATEZOLIZUMAB (Tecentriq) PA packet
Open ApprovalHelp — generate a ATEZOLIZUMAB (Tecentriq) prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com